Clinical and Patient-Reported Outcomes of Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C Among Patients on Opioid Agonist Treatment: A Real-world Prospective Cohort Study.
direct-acting antivirals
hepatitis C virus
opioid substitution treatment
patient-reported outcome measures
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
08
04
2020
accepted:
07
08
2020
entrez:
3
9
2020
pubmed:
3
9
2020
medline:
3
9
2020
Statut:
epublish
Résumé
Patient-reported outcomes (PROs) can help to reduce uncertainties about hepatitis C virus (HCV) treatment with direct-acting antivirals (DAAs) among people who inject drugs and increase treatment uptake in this high-risk group. Besides clinical data, this study analyzed for the first time PROs in a real-world sample of patients on opioid agonist treatment (OAT) and HCV treatment with DAAs. HCV treatment data including virological response, adherence, safety, and PROs of 328 German patients on OAT were analyzed in a pragmatic prospective cohort study conducted from 2016 to 2018. Clinical effectiveness was defined as sustained virological response (SVR) at week 12 after end of treatment and calculated in per-protocol (PP) and intention-to-treat (ITT) analyses. Changes over time in PROs on health-related quality of life, physical and mental health, functioning, medication tolerability, fatigue, concentration, and memory were analyzed by repeated-measures analyses of variances (ANOVAs). We found high adherence and treatment completion rates, a low number of mainly mild adverse events, and high SVR rates (PP: 97.5% [n = 285]; ITT: 84.5% [n = 328]). Missing SVR data in the ITT sample were mainly caused by patients lost to follow-up after treatment completion. Most PROs showed statistically significant but modest improvements over time, with more pronounced improvements in highly impaired patients. This real-world study confirms that DAA treatment among OAT patients is feasible, safe, and effective. PROs show that all patients, but particularly those with higher somatic, mental, and social burden, benefit from DAA treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Patient-reported outcomes (PROs) can help to reduce uncertainties about hepatitis C virus (HCV) treatment with direct-acting antivirals (DAAs) among people who inject drugs and increase treatment uptake in this high-risk group. Besides clinical data, this study analyzed for the first time PROs in a real-world sample of patients on opioid agonist treatment (OAT) and HCV treatment with DAAs.
METHODS
METHODS
HCV treatment data including virological response, adherence, safety, and PROs of 328 German patients on OAT were analyzed in a pragmatic prospective cohort study conducted from 2016 to 2018. Clinical effectiveness was defined as sustained virological response (SVR) at week 12 after end of treatment and calculated in per-protocol (PP) and intention-to-treat (ITT) analyses. Changes over time in PROs on health-related quality of life, physical and mental health, functioning, medication tolerability, fatigue, concentration, and memory were analyzed by repeated-measures analyses of variances (ANOVAs).
RESULTS
RESULTS
We found high adherence and treatment completion rates, a low number of mainly mild adverse events, and high SVR rates (PP: 97.5% [n = 285]; ITT: 84.5% [n = 328]). Missing SVR data in the ITT sample were mainly caused by patients lost to follow-up after treatment completion. Most PROs showed statistically significant but modest improvements over time, with more pronounced improvements in highly impaired patients.
CONCLUSIONS
CONCLUSIONS
This real-world study confirms that DAA treatment among OAT patients is feasible, safe, and effective. PROs show that all patients, but particularly those with higher somatic, mental, and social burden, benefit from DAA treatment.
Identifiants
pubmed: 32875003
doi: 10.1093/ofid/ofaa317
pii: ofaa317
pmc: PMC7452367
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofaa317Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
J Hepatol. 2019 Sep;71(3):486-497
pubmed: 31096006
Med Care. 1996 Mar;34(3):220-33
pubmed: 8628042
Int J Drug Policy. 2019 Jan;63:29-38
pubmed: 30476876
PLoS One. 2016 Nov 15;11(11):e0166451
pubmed: 27846264
J Clin Transl Hepatol. 2019 Jun 28;7(2):172-182
pubmed: 31293918
Clin Infect Dis. 2019 Nov 02;:
pubmed: 31677262
BMC Med Res Methodol. 2017 Jan 26;17(1):14
pubmed: 28125960
J Viral Hepat. 2018 Dec;25(12):1507-1514
pubmed: 30141236
J Clin Epidemiol. 2005 Feb;58(2):142-9
pubmed: 15680747
Addiction. 2018 May;113(5):868-882
pubmed: 29359361
Clin Infect Dis. 2020 May 6;70(10):2199-2205
pubmed: 31631215
BMC Infect Dis. 2017 Aug 3;17(1):541
pubmed: 28774261
J Infect Dis. 2018 Mar 13;217(7):1033-1043
pubmed: 29293991
Clin Infect Dis. 2020 May 23;70(11):2355-2365
pubmed: 31513710
Int J Appl Basic Med Res. 2015 May-Aug;5(2):82
pubmed: 26097811
World J Gastroenterol. 2019 May 14;25(18):2229-2239
pubmed: 31143073
J Transl Int Med. 2017 Jun 30;5(2):112-119
pubmed: 28721344
Expert Rev Gastroenterol Hepatol. 2017 Mar;11(3):259-268
pubmed: 28116926
Clin Infect Dis. 2013 Aug;57 Suppl 2:S97-104
pubmed: 23884073
Int J Drug Policy. 2018 Dec;62:74-77
pubmed: 30368101
Br J Addict. 1991 Oct;86(10):1317-22
pubmed: 1751847
Clin Gastroenterol Hepatol. 2018 Apr;16(4):567-574.e6
pubmed: 29155352
Patient. 2019 Apr;12(2):259-265
pubmed: 30270403
PLoS One. 2018 Mar 26;13(3):e0194162
pubmed: 29579073
Gut. 2018 Mar;67(3):553-561
pubmed: 28634198
J Hepatol. 2019 Jul;71(1):45-51
pubmed: 30853642
J Clin Epidemiol. 2017 Sep;89:136-141
pubmed: 28433678
PLoS One. 2018 Nov 30;13(11):e0207226
pubmed: 30500863
Infect Dis Ther. 2018 Sep;7(3):373-385
pubmed: 30076582
J Subst Abuse Treat. 2017 Apr;75:49-53
pubmed: 28237054
Lancet Glob Health. 2017 Dec;5(12):e1192-e1207
pubmed: 29074409
J Hepatol. 2019 Dec;71(6):1116-1125
pubmed: 31433302
Subst Abuse Treat Prev Policy. 2019 Jan 3;14(1):2
pubmed: 30606188
PLoS One. 2019 May 3;14(5):e0215596
pubmed: 31050687
J Hepatol. 2015 Aug;63(2):337-45
pubmed: 25795586
Open Forum Infect Dis. 2018 Feb 09;5(2):ofy001
pubmed: 29450210
Int J Drug Policy. 2019 Oct;72:77-83
pubmed: 31221475